Dr. Josep Llovet is a world-renowned hepatic oncologist whose pioneering work has transformed the landscape of liver cancer research and treatment. He currently serves as an ICREA Research Professor at IDIBAPS-Hospital Clínic and Full Professor of Medicine-Hepatic Oncology at the University of Barcelona, where he leads the Translational Research Group in Hepatic Oncology. After obtaining his medical degree from the University of Barcelona in 1986 and his PhD from the Autonomous University of Barcelona, he established himself as a leading authority in liver cancer through his dual appointments at prominent institutions in Barcelona and New York. His strategic leadership extends to his role as Director of the Liver Cancer Program at the Icahn School of Medicine at Mount Sinai, where he has built a comprehensive research enterprise that bridges basic science and clinical applications.
Dr. Llovet's groundbreaking research has fundamentally reshaped the understanding and treatment of hepatocellular carcinoma and cholangiocarcinoma through his identification of molecular and immune classification systems that guide personalized therapeutic approaches. His seminal work defining the molecular drivers of liver cancer has led directly to the development and establishment of standard therapies including sorafenib, regorafenib, ramucirumab, and innovative combinations like TACE plus lenvatinib and pembrolizumab. With an impressive publication record of 376 manuscripts accumulating over 124,000 citations and an h-index of 141, he has been recognized as a top 1% most cited researcher globally by Clarivate Analytics for over a decade and is acknowledged as the world's most cited investigator in liver cancer. His leadership of the European HEPTROMIC project and coordination of multiple NIH and European grants have catalyzed international collaboration in the field of liver cancer research.
Beyond his research achievements, Dr. Llovet has profoundly influenced the global liver cancer community through his founding role in the International Liver Cancer Association and his editorship of the Journal of Hepatology Reports, which maintains an impact factor of 9.5. He has delivered over 700 lectures worldwide and trained numerous researchers who have gone on to advance the field of hepatic oncology across multiple continents. His current research focuses on identifying biomarkers for immunotherapy response, characterizing molecular mechanisms in obesity and diabetes-related HCC, and leading the HUNTER-Hepatocellular Carcinoma Expediter Network to accelerate therapeutic development. As he continues to push the boundaries of translational medicine in liver cancer, Dr. Llovet remains at the forefront of developing precision approaches that promise to improve outcomes for patients with these challenging malignancies.
